Pharmacotherapy for the Elderly Dental Patient
Body Download PDF Abstract Current demographic data clearly show that the North American population is aging, and projections suggest that the percentage of older
Body Download PDF Abstract Current demographic data clearly show that the North American population is aging, and projections suggest that the percentage of older
Body Download PDF Abstract Background: Adverse effects of medication used in dental care are likely to increase as North Americans live longer, experience more
Body Download PDF Abstract Direct thrombin inhibitors, specifically orally administered dabigatran etexilate, are emerging as alternatives to warfarin for anticoagulation in the management of
Body Abstract With the increasing use of the bisphosphonate class of drugs, dental professionals are encountering more cases of bisphosphonate-related osteonecrosis of the jaw
Body I would like to describe for JCDA readers a technique that we have found to be useful in administering perioperative capsules and pills
Body Download PDF Abstract Patients undergoing cancer chemotherapy are living longer and with better quality of life, and they require dental care both during
Body The news item1 that appeared in the recent issue of JCDA implies that CDA, the American Dental Association (ADA), and the American Academy of
Body Thromboembolic events are among the major causes of mortality and morbidity.1 To decrease the incidence of such events, physicians prescribe one or more antithrombotic
Body JCDA has recently featured several articles and clinical resources related to antibiotic prophylaxis. For your reference, links to the articles and related resources are
Body Download PDF ABSTRACT Objective: Long-term use of phenytoin (PHT) causes gingival hyperplasia; however, little is known about the oral side effects of other
Body Dentists can now access a patient resource on bisphosphonates as they relate to oral health. This class of medications has been examined extensively, to
Body Health Canada published an updated advisory notice in April, reminding the public about the potential health risks of topical benzocaine products. This follows its